Stroke is the leading cause of disability and thesecond leading cause of death worldwide.
With the global population aged 65 and over growing faster than all other age groups, the …

While the mainstay of acute stroke treatment includes revascularization via recombinant
tissue plasminogen activator or mechanical thrombectomy, only a minority of stroke patients …

Stroke is the third cause of death worldwide and the main cause of chronic, severe adult
disability. We focus on acute ischaemic stroke, which accounts for approximately 80% of all …

The prescribed use of pharmaceuticals can result in unintended, unwelcomed, and
potentially adverse consequences for the environment and for those not initially targeted for …

Intravenous thrombolysis via tPA (tissue-type plasminogen activator) is the only approved
pharmacological treatment for acute ischemic stroke, but its benefits are limited by …

In recent years, stroke-induced immunodepression syndrome (SIDS) and the resulting
stroke-associated infection (SAI) have become a focus of current research efforts …

Pathophysiological processes of stroke have revealed that the damaged brain should be
considered as an integral structure to be protected. However, promising neuroprotective …

Neurological disorders affect the nervous system. Biochemical, structural, or electrical
abnormalities in the spinal cord, brain, or other nerves lead to different symptoms, including …

Despite the impressive efficacies demonstrated in preclinical research, hundreds of
potentially neuroprotective drugs have failed to provide effective neuroprotection for …

Background and Purpose—The STARS trial (Stroke Treatment With Acute Reperfusion and
Simvastatin) was conducted to demonstrate the efficacy and safety of simvastatin treatment …